Appendix 4C - Quarterly - 31 March 2021
Filed with ASX · · 9 pages · English
Melbourne, Australia; 28 April 2021: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2021. Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said:“We are extremely pleased with the significant progress we h
Story so far
Earlier from Patrys
- New United States patent granted for Patrys deoxymab assets
- Appendix 4D - Half Year Accounts - 31 December 2020
- Patrys Successfully Establishes PAT-DX1 Stable Cell Line
- Appendix 4C - Quarterly - 31 December 2020
- $7.3M Capital Raising
Later from Patrys
- Patrys receives R&D Tax Incentive refund
- Paper highlights PAT-DX1 as potential brain cancer treatment
- Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight
- Response to ASX Query
- Full size deoxymab PAT-DX3 crosses the blood brain barrier
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys